Essential Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Essential Partners’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$852	Hold	80	–	–	﹤0.01%	2242
2026 Q2	$860	Buy	80 +42	+111%	+$343	﹤0.01%	2304
2026 Q1	$234	Buy	38 +14	+58%	+$108	﹤0.01%	2581
2025 Q4	$185	Hold	24	–	–	﹤0.01%	2445
2025 Q3	$225	Hold	24	–	–	﹤0.01%	2378
2025 Q2	$199	Buy	+24	New	+$164	﹤0.01%	1943

Other funds holding FENC

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's FENC Position: Q3 2026 in Review

Essential Partners held its Fennec Pharmaceuticals (FENC) position steady in Q3 2026 at 80 shares worth $852. The position accounts for ﹤0.01% of the portfolio, ranked #2242.

Essential Partners first reported a position in FENC in Q2 2025 and has held it in 6 quarters since. The position peaked at $860 in Q2 2026. 11 funds tracked by Wall St. Rank hold FENC as of Q3 2026.

Essential Partners held 80 shares of Fennec Pharmaceuticals worth $852 as of Q3 2026.
Essential Partners left its Fennec Pharmaceuticals share count unchanged in Q3 2026.
Fennec Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2242 holding.
Essential Partners first reported a position in Fennec Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Fennec Pharmaceuticals position peaked at $860 in Q2 2026.
11 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.